Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

NOXXON’s oncology-focused pipeline acts by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the tumor micro-environment (TME), NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, lead program NOX-A12 has delivered top-line data from a combination trial with the immuno-oncology checkpoint inhibitor, Keytruda®, in metastatic colorectal and pancreatic cancer patients in December 2018 and further studies are being planned in these indications. NOXXON has initiated preparations for an additional trial with NOX-A12 in brain cancer in combination with radiotherapy. The combination of NOX-A12 and radiotherapy has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. The company’s second clinical-stage asset, NOX-E36 is a Phase 2 ready TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors both as a monotherapy and in combination.

 

• Download the initiation report on NOXXON by Aurgalys
➥ See latest update note from Aurgalys here
• Download the re-initiation report (Dec 2018) on NOXXON by Invest Securities
 

 

Press Release

Berlin, Germany

2019, April 12
7:00 p.m.

NOXXON Pharma N.V. reports 2018 financial results

2019, April 01
7:00 p.m.

NOXXON presents updated results from Phase 1/2 NOX-A12 / Keytruda combination trial at AACR 2019

2019, February 28
7:00 p.m.

NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting


Events

Aram Mangasarian
April 30 – May 2, London, UK

Aram Mangasarian
May 13-15, Frankfurt, Germany

Aram Mangasarian, Jarl Ulf Jungnelius
May 31 – June 4, Chicago, IL, US